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Abstract: COPD is a common and highly destructive disease with huge impacts on people
and health services throughout the world. It is mainly caused by cigarette smoking though
environmental pollution is also significant. There are no current treatments that affect the
overall course of COPD; current drugs focus on symptomatic relief and to some extent
reducing exacerbation rates. There is an urgent need for in-depth studies of the fundamental
pathogenic mechanisms that underpin COPD. This is vital, given the fact that nearly 40%–
60% of the small airway and alveolar damage occurs in COPD well before the first
measurable changes in lung function are detected. These individuals are also at a high risk
of lung cancer. Current COPD research is mostly centered around late disease and/or innate
immune activation within the airway lumen, but the actual damage to the airway wall has
early onset. COPD is the end result of complex mechanisms, possibly triggered through
initial epithelial activation. To change the disease trajectory, it is crucial to understand the
mechanisms in the epithelium that are switched on early in smokers. One such mechanism
we believe is the process of epithelial to mesenchymal transition. This article highlights the
importance of this profound epithelial cell plasticity in COPD and also its regulation. We
consider that understanding early changes in COPD will open new windows for therapy.
Keywords: epithelial-to-mesenchymal transition, EMT, cancer, fibrosis, inflammation, HuR,
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Background
COPD is a devastating disease of the lung found mainly to affect cigarette
smokers, though fossil-based air pollution in developing nations is now consid-
ered an equal contributor. The WHO estimates that there are over 250 million
persons affected by the disease, which accounts for at least 3 million deaths
annually as of 2015, which roughly averages around 5% of total worldwide
reported mortality.1 The disease is characterized clinically as a slowly progres-
sive airway narrowing with only partial reversibility at best. In vulnerable
smokers, the entire lung is affected2 which is evident from the development of
large airway squamous metaplasia, mucus hypersecretion and smooth muscle
hyperplasia along with increases in small airway fibrosis and airway wall
thickening.3,4 These changes affect the normal airway architecture, subsequently
causing airway narrowing and obliteration, accompanied by bronchitis.5 It is
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also notable that patients also suffer from varying
degrees of emphysematous lung destruction,6,7 which
significantly adds to airflow limitation.5
The epithelial lining forms the outer layer of the lung
mucosa and thus is the first line of defense for any external
insults.10 These cells act as a barrier to infectious microbes
and toxic particles emanating from entities such as smoke,
via increased mucus secretion and ciliary clearance; how-
ever, in chronic conditions, the mucus is often thickened
with phlegm and impaired ciliary function.5 Epithelial
cells also produce various antibacterial, antioxidant, anti-
protease factors and have tight epithelial junctions11 and
thus deny entry of foreign entities and stop them from
damaging the inner lung mucosa.12 Nevertheless, chronic
exposure to these external insults causes observable
changes to the normal architecture of the epithelium in
both smokers and COPD patients13 with increases in basal
cell abnormalities and decreases in epithelial cellular junc-
tion integrity.14,15 Ultimately, the changes associated have
a direct impact on disease outcome wherein almost half of
the small airways are lost at early stages of the disease.
Findings by Koo et al8 provided evidence to this effect,
demonstrating that both small airways and alveolar struc-
tures are damaged in early COPD. Terminal bronchioles
number obliterated by 40% in patients with mild-to-mod-
erate COPD patients. Interestingly, transitional bronchioles
numbers reduced in both mild and mild-to-moderate
patients by 55%, and alveolar surface area decreased by
40%.8 Further, total airway count has also been shown to
decrease by 19% in both mild-to-moderate COPD com-
pared to never smokers.9
This devastating effect on the lung of early COPD
patients can be attributed to active remodeling, whose
impact on disease progression and manifestation needs
further recognition. In this commentary, we wish to high-
light the factors that contribute to such changes and the
role of post-transcriptional regulators such as human anti-
gen R (HuR) as possible modulators to these responses.
In both COPD patients and active smokers, cellular repro-
gramming in epithelial cells14 consequently could lead to
epithelial–mesenchymal transition (EMT),16 a process where
epithelial cells progressively lose cellular polarity and, adhe-
siveness, become migratory and assume a mesenchymal
phenotype.17–19 Previous findings have established the pre-
sence of EMT in other fibrotic diseases and cancers,20–22 but
recent studies have increasingly considered EMT as the pos-
sible core pathological factor in the development of COPD as
well.23–27 Indeed, studies now show that the epithelium of
COPD patients has increased cellular expression of mesench-
ymal markers such as S100A4 and vimentin,28 which is espe-
cially higher in basal cells and is omnipresent in both large and
small airways.26,29,30 The other characteristic EMT feature is
reticular basement membrane (Rbm) fragmentation which
was found to be higher in COPD patients than in nonsmokers,
and this has been attributed to increase in epithelial matrix
metalloprotease (MMP) activity especially of MMP-9 (col-
lagenase/gelatinase).31 In the same set of patients, increased
Rbm vascularity was also observed, which is another promi-
nent feature of EMT leading to the formation of a pro-cancer
stroma.32 The increased expression of mesenchymal markers
S100A4 and vimentin negatively correlated with lung func-
tion, suggesting a physiological consequence.26 COPD ex-
smokers had significantly less Rbm S100A4 expression and
a similar trend was observed for Rbm vessels.33,34 Appropriate
smoking cessation studies are needed to further confirm these
findings, but certainly, it seems to be making a difference.
Initial proof of concept trial by our group revealed that inhaled
corticosteroids (ICS) such as fluticasone propionate were
effective in decreasing mesenchymal expression of S100A4
and vimentin, along with significant reduction in Rbm frag-
mentation, EGFR and MMP-9 expression in the COPD group
compared to placebo.35 The study provided sufficient rationale
for translational strategies that can be employed with currently
available therapies to overcome this pathological aspect.35,36
Epidemiological studies have also revealed that ICS are asso-
ciated with reduced lung cancer risks in COPD patients, which
might be again through the anti-EMT effects of ICS.37 Milara
et al38 in their in vitro studies found that cigarette smoke
extract (CSE) does induce EMT activity in normal primary
bronchial epithelial cells (pHBECs) via ROS generation,
which enhanced TGFβ1 expression while decreasing cyclic
adenosine monophosphate (cAMP) levels. Further, the group
demonstrated that EMT could be attenuated by elevating
cAMP levels using a specific phosphodiesterase 4 inhibitor.38
Gohy et al observed that targeting TGF-β1 expression via
specific monoclonal antibodies, during in vitro differentiation
of pHBECs, reduced mesenchymal vimentin expression and
fibronectin release.39 Similar increases in mesenchymal mar-
kers N-cadherin and α-smooth muscle actin (αSMA) were
reported by Wang et al, with an associated decrease in E-
cadherin and α-catenin in small airway epithelial cells when
stimulated in vitro with CSE. They further found that uroki-
nase plasminogen activation receptor could be responsible for
modulating EMT, positively correlating with an increase in
vimentin expression in human small airways.40 Recent in vitro
epithelial–fibroblast co-culture studies also examined the
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probable role of IL-1α in promoting EMT.41 They reported
that IL-1α caused aberrant epithelial–fibroblast interactions
when stimulated by CSE.42
Although there are now several studies suggesting upre-
gulation of EMTmarkers in COPD, there have only been few
molecular signaling pathway studies undertaken to elucidate
the underlying mechanisms of EMT in COPD. Recent stu-
dies suggest that EMT in smokers and early (mild to moder-
ate) COPD patients is likely driven by the activation of
canonical pathways associated with TGFβ,43 which induces
increases in the expression of nuclear transcription factors
such as pSMAD2/3 with simultaneous reduction of inhibi-
tory SMAD6/7 expression.44–46 The increased expression of
pSMAD2/3 negatively correlated with lung function in
patients with COPD, which indicates possible physiological
consequences.44 Although pathways triggered by TGFβ and
its superfamily, including bone morphogenetic proteins
(BMPs) and growth differentiation factors (GDFs), play
vital roles,47 other canonical pathways such as Wingless/
integrase-1 (Wnt)-mediated epithelial changes could also be
crucial in COPD EMT pathology. However, there are few
literature evidence in COPD. Our group observed enhanced
expression of β-catenin in the large airways of both smokers
and COPD, though COPD patients were observed to have
increased nuclear to cytoplasmic ratio of β-catenin expres-
sion suggesting active translocation and possible transcrip-
tion of genes associated with mesenchymal proteins.48
Further, in vitro studies with bronchial epithelial cells
showed that nicotine, which is a major component of tobacco
smoke, could induce EMT in a WNT-3A/β-catenin-depen-
dent manner.49 In the peripheral tissue, it was demonstrated
that a decrease in Wnt/β catenin signaling was involved in
parenchymal tissue impairment and associated disruption of
repair mechanism, leading to an increase in emphysema in
COPD patients.50 Again, this decrease may be further aug-
mented by the lack of frizzled (FZD) receptors in the periph-
eral tissue, effectively enhancing the impairment process in
alveolar cells.51 Interestingly, non-canonical pathways of
Wnt signaling were found to be active in bronchial epithelial
cells of COPD patients compared to smokers and
nonsmokers.52 Wnt5B was found to modulate EMT changes
independent of β-catenin possibly through the induction of
TGFβ/SMAD3 signaling.53 Moreover, evidence also sug-
gests cross-talk between TGFβ/SMADs and Wnt/β-catenin
pathways in TGFβ-induced alveolar epithelial cells, and that
these interactions synergize to increase the expression of
αSMA, a hallmark of EMT.54,55 Transcriptional factors
such as SNAIL1/2, ZEB1/2 and TWIST, which are
independently activated by canonical or non-canonical path-
ways also show increased epithelial nuclear translocation in
COPD patients.48 Other potential interactive pathways were
demonstrated to enhance EMT changes, for example, TGF-
β1 and p38 MAPK/PI3K/Akt signaling pathways comple-
ment each other and are known to activate SMAD2/3 signal-
ing in in vivo models of COPD and in lung cancer.56 Further,
an increase in EGFR ligand HB-EGF in smokers and COPD
was also observed to potentiate EMT-related and airway
modeling changes possibly by interacting and modulating
TGFβ pathways.57,58 Considering the complexity in the num-
ber of pathways involved would indeed be hard to pinpoint
one pathway which could be specifically targeted to inhibit
this profound epithelial plasticity. However, given the pub-
lished evidence in the literature, it is now almost certain that
EMT does play an important role in COPD pathology.
In line with these findings in EMT, recent study by
Sun et al59 provided vital initial evidence of the post-
transcriptional regulatory pathways that are involved in
modulating EMT in COPD patients. Their study espe-
cially investigates the role of (HuR, which is an ubiqui-
tously expressed post-transcriptional regulator of RNA
synthesis and regulates several proteins including the
ones involved in EMT. HuR are members of the ELAV/
Hu family of RNA-binding proteins (RBP), specifically
bind to AU (SRE) sites of the 3’-end of the mRNA of
several growth factors, transcription factor proteins, cell
cycle regulators and plays the crucial role in translocating
mRNA from the nucleus to the cytoplasm for protein
translation purposes.60 Once in the cytoplasm HuR
effects mRNA stability and translation of EMT-associated
proteins (Figure 1). Sun et al59 demonstrate that the
levels of HuR expression are significantly increased in
both smokers and COPD patients but more substantially
in the latter group suggesting the possibility of a COPD
effect. The cytoplasmic HuR expression was also shown
to increase in human bronchial epithelial immortalized
cell lines such as BEAS-2B when treated with cigarette
smoke extracts (CSE). Most interestingly and relevant to
EMT was their finding of a close association of cytoplas-
mic HuR levels and increases in the EMT trans-nuclear
transcription factor ZEB1. The finding of increasingly
stable mRNA levels of ZEB1 indicates that the translo-
cated cytoplasmic HuR may play a direct role in modula-
tion of ZEB1, which again was evidently higher in the
epithelium of smokers and COPD patients compared to
nonsmoking controls.59 There are only a few other stu-
dies that demonstrate HuR having a direct role in driving
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EMT in COPD. A recent study by Gu et al has shown
that in vitro CSE induces changes in small airway epithe-
lial cells by increasing the expression of EMT-promoting
proteins such as vimentin and SNAIL while decreasing
the expression of E-cadherin in these cells. This increase
in the cellular content of EMT proteins was found to be
diminished in cells treated with siRNA targeting HuR.61
This inhibitory action by silencing HuR was also demon-
strated by Sun et al59 wherein siRNA against HuR
reduced ZEB-1 protein expression and decreased E-cad-
herin while increasing the expression of mesenchymal
marker such as vimentin. Previous studies in cancer
showed that HuR modulates EMT regulators such as
SNAIL and Wnt/β-Catenin by stabilizing their protein
levels in the cytoplasm.60,62 Considering the fact that
both these transcription factors and HuR are upregulated
in COPD patients, investigating the possible role of HuR
in their regulation is important. One of the key comor-
bidities of COPD patients is lung cancer. Indeed, epithe-
lia with active EMT63 are potentially vulnerable to
malignant transformation, and EMT in COPD airways
may well be the vital link between airway fibrosis and
cancer development.64 Recently, our group showed strong
correlations between EMT activity in the leading edge of
invasive cancer and EMT activity in the nonmalignant
airway areas from which the tumor originated.65 Thus,
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Figure 1 The figure illustrates the cellular pathways associated with EMT and HuR as a modulator regulating the changes in smokers and COPD. Both TGFβ and Wnt
pathways play a crucial role in inducing EMT and potentially activate their associated receptors TGFβR and Frizzled, respectively. Activation of TGFβ-TGFβR results in
phosphorylation of SMAD2/3 which tags with SMAD4 and translocates into the nucleus causing transcriptional changes. Activation of Wnt-Frizzled receptor signaling leads
to inhibition of GSK3β and consequential accumulation of cytoplasmic β-catenin. The free β-catenin translocates into the nucleus and regulates target gene transcription.
Finally, both pathways could lead to the induction of EMT with increases in mesenchymal and corresponding decreases in epithelial proteins. HuR, under pathological
conditions, translocates from peri-nuclear into the cytoplasm and enhances further synthesis and stabilization of these translocating nuclear proteins, thus increasing the
potential of EMT.
Abbreviations: EMT, epithelial–mesenchymal transition; HuR, human antigen R.
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increased expression of HuR and associated EMT in
COPD patients suggest a potential therapeutic target
with relevance in early COPD to cancer transition.66
Also, EMT as a process could lead to an increase in
fibroblastic cell populations that can invade the underlying
mucosa, potentially causing airflow limitation in COPD,
especially in the small airways wherein tissue reconfiguration
and scarring occurs. Further, active fibroblasts can cause
aberrant changes to the extracellular matrix (ECM) leading
to an increase in airway wall thickening, stiffness and gradual
obliteration of the small airways.26,65 Although EMT seems
to be a major contributor of fibroblasts, other sources which
include fibrocytes, pericytes, residential fibroblasts and
mesenchymal cells could also be contributing to the overall
population of fibroblasts.67 Interestingly, endothelial cells
which are themajor cell type in blood vessels and responsible
for structure and function possess the propensity to transit
into fibroblast, through the process of endothelial-to-
mesenchymal transition.18,34,68 During this process, endothe-
lial cells lose endothelial adherence proteins such as VE-
cadherins and gain mesenchymal markers similar to
EMT.69 Under pathological conditions such as in chronic
lung disease, fibroblasts are further transformed to their
more active form, myofibroblasts.3 These cells appear to
have spindle-shaped morphology and are highly contractile.
The migratory potential of myofibroblasts directly relates to
the increased expression of αSMA myofilaments, which
forms nonmuscle cells (stress fibers). Myofibroblasts are
known to secrete a broad array of ECM proteins, which
include fibrous proteins such as collagen and elastin, as
well as glycoproteins such as fibronectin, tenascin C and
various forms of proteoglycans.70 Both canonical, Wnt/β-
catenin and TGFβ/SMAD pathways are active in fibroblasts
and their induction promotes myofibroblast proliferation and
generation of ECM proteins.71,72 Thus, understanding the
role of HuR in stabilizing proteins that induce these changes
in fibroblast and myofibroblast populations is important and
requires further investigation.73
Finally, another major aspect in COPD is identifying the
role played by inflammation and infections in driving
epithelial and other cellular transformations.3,74–76 Our
group recently observed an overall reduction in total airway
wall cellularity that further corresponded to either decrease
or nonsignificant changes in key innate immune cells such
as macrophage and neutrophils in COPD patients.77 On
further evaluation of macrophage subpopulation in the
bronchoalveolar lavage of COPD patients, we observed
increases in M2 compared to M1 macrophage polarization
which matched the cytokine profile.78 M2/Th2 cytokines
are known to suppress M1-related inflammation, induce
epithelial plasticity and promote proliferation of
fibroblasts.79–81 Evidence also suggest dysfunctional
immunity82 in COPD patients74–76 with poor phagocytic
bacterial clearance by macrophage and ineffective killing
of viral-infected cells by cytotoxic Tcells.83,84 Interestingly,
previous studies in colorectal cancer demonstrated that
increases in cytoplasmic HuR in macrophages led to the
suppression of pro-inflammatory cytokines, dysfunctional
immunity and M2 polarisation.85,86 Thus, it would be of
intrinsic value to evaluate the role of HuR in regulating
inflammation in COPD and other chronic lung diseases.
Conclusions
We consider that EMT has important implications in various
aspects of COPD and are crucial to large and small airway
pathology, for both fibrosis and lung cancer.87,88 The role of
TGFβ and Wnt pathways is implicated in these transforma-
tions and could have a potential difference in activity in the
lung based on the affected region. This is a novel field in
COPD, though could have wider implications in other
chronic lung diseases as well. The role of HuR in the regula-
tion of EMTand disease manifestations makes it an attractive
target for therapeutic strategies; however, further research in
this area is mandated. ICS do prevent against lung cancer risk
in COPD, which may be through EMT. However, a safer
drug than ICS is needed for long-term use.
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